blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3102213

EP3102213 - PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.02.2021
Database last updated on 16.07.2024
FormerThe patent has been granted
Status updated on  28.02.2020
FormerGrant of patent is intended
Status updated on  27.10.2019
FormerRequest for examination was made
Status updated on  14.09.2019
FormerGrant of patent is intended
Status updated on  13.05.2019
FormerRequest for examination was made
Status updated on  11.11.2016
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Galapagos NV
Generaal De Wittelaan L11/A3
2800 Mechelen / BE
[2016/50]
Inventor(s)01 / DE WEER, Marc Maurice Germain
Galapagos NV Generaal De Wittelaan L11/A3
2800 Mechelen / BE
02 / VRIELYNCK, Sara Bertha Camiel
Galapagos NV Generaal De Wittelaan L11/A3
2800 Mechelen / BE
03 / SABOURAULT, Nicolas Luc
Galapagos SASU 102 Avenue Gaston Roussel
93230 Romainville / FR
04 / MOESCHWITZER, Jan Peter
Fontanestrasse 37
15344 Straussberg / DE
 [2016/50]
Representative(s)Bar, Grégory
Galapagos NV
IP Department
Generaal De Wittelaan, L11 A3
2800 Mechelen / BE
[2016/50]
Application number, filing date15705777.904.02.2015
[2016/50]
WO2015EP52239
Priority number, dateGB2014000207007.02.2014         Original published format: GB 201402070
[2016/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015117980
Date:13.08.2015
Language:EN
[2015/32]
Type: A1 Application with search report 
No.:EP3102213
Date:14.12.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 13.08.2015 takes the place of the publication of the European patent application.
[2016/50]
Type: B1 Patent specification 
No.:EP3102213
Date:01.04.2020
Language:EN
[2020/14]
Search report(s)International search report - published on:EP13.08.2015
ClassificationIPC:A61K31/541, A61K9/20, A61K9/48, A61K31/437
[2016/50]
CPC:
A61K9/2054 (EP,US); A61K47/32 (US); A61K31/541 (EP,US);
A61K45/06 (US); A61K47/02 (US); A61K47/38 (US);
A61K47/44 (US); A61K9/4866 (EP,US); A61P11/06 (EP);
A61P17/06 (EP); A61P19/00 (EP); A61P19/02 (EP);
A61P29/00 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P5/14 (EP); A61P9/10 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/50]
Extension statesBA01.09.2016
ME01.09.2016
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON ENTZÜNDUNGSERKRANKUNGEN[2016/50]
English:PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS[2016/50]
French:COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DES MALADIES INFLAMMATOIRES[2019/03]
Former [2016/50]COMPOSITIONS PHARMACEUTIQUES DESTINÉES AU TRAITEMENT DES TROUBLES INFLAMMATOIRES
Entry into regional phase01.09.2016National basic fee paid 
01.09.2016Designation fee(s) paid 
01.09.2016Examination fee paid 
Examination procedure01.09.2016Examination requested  [2016/50]
01.09.2016Date on which the examining division has become responsible
16.03.2017Amendment by applicant (claims and/or description)
14.05.2019Communication of intention to grant the patent
11.09.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.10.2019Communication of intention to grant the patent
20.02.2020Fee for grant paid
20.02.2020Fee for publishing/printing paid
20.02.2020Receipt of the translation of the claim(s)
Opposition(s)12.01.2021No opposition filed within time limit [2021/11]
Fees paidRenewal fee
10.02.2017Renewal fee patent year 03
14.02.2018Renewal fee patent year 04
13.02.2019Renewal fee patent year 05
13.02.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.02.2015
AL01.04.2020
CY01.04.2020
CZ01.04.2020
EE01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
MK01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
[2024/22]
Former [2023/30]HU04.02.2015
AL01.04.2020
CY01.04.2020
CZ01.04.2020
EE01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2023/27]HU04.02.2015
AL01.04.2020
CZ01.04.2020
EE01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/41]AL01.04.2020
CZ01.04.2020
EE01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
MC01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/24]AL01.04.2020
CZ01.04.2020
EE01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SI01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/10]AL01.04.2020
CZ01.04.2020
EE01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
PL01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SK01.04.2020
SM01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/09]AL01.04.2020
CZ01.04.2020
EE01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
RO01.04.2020
RS01.04.2020
SE01.04.2020
SM01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2021/04]AL01.04.2020
CZ01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
RS01.04.2020
SE01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/51]CZ01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
RS01.04.2020
SE01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/50]CZ01.04.2020
FI01.04.2020
LT01.04.2020
LV01.04.2020
SE01.04.2020
BG01.07.2020
GR02.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/49]CZ01.04.2020
FI01.04.2020
LT01.04.2020
SE01.04.2020
BG01.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/48]FI01.04.2020
LT01.04.2020
SE01.04.2020
BG01.07.2020
IS01.08.2020
PT17.08.2020
Former [2020/47]LT01.04.2020
BG01.07.2020
IS01.08.2020
Former [2020/46]BG01.07.2020
IS01.08.2020
Former [2020/39]BG01.07.2020
Cited inInternational search[XI]US2010029709  (MENET CHRISTEL JEANNE MARIE [BE], et al) [X] 1-4,14,15,17-22 * paragraphs [0217] - [0219] - [0225] - [0229] * * example -; claim - * [I] 5-13,16;
 [XI]US2013310340  (PAYAN DONALD G [US], et al) [X] 1-5,7,10,14-22 * paragraphs [0275] - [0286] * * claim - *[I] 6,8,9,11-13
by applicantWO2010149769
    - BERISHAJ, M.; GAO, S.P.; AHMED, S.; LESLIE, K.; AL-AHMADIE, H.; GERALD, W.L.; BORNMANN, W.; BROMBERG, J.F., "Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer", BREAST CANCER RES. BCR, (2007), vol. 9, page R32
    - CONSTANTINESCU, S.N.; GIRARDOT, M.; PECQUET, C., "Mining for JAK-STAT mutations in cancer", TRENDS BIOCHEM. SCI., (2008), vol. 33, pages 122 - 131
    - DOLGIN, E., "Companies hope for kinase inhibitor JAKpot", NAT. REV. DRUG DISCOV., (2011), vol. 10, pages 717 - 718
    - INGERSOLL, K.S.; COHEN, J., "The impact of medication regimen factors on adherence to chronic treatment: a review of literature.", J. BEHAV. MED., (2008), vol. 31, pages 213 - 224
    - KOPF, M.; BACHMANN, M.F.; MARSLAND, B.J., "Averting inflammation by targeting the cytokine environment", NAT. REV. DRUG DISCOV., (2010), vol. 9, pages 703 - 718
    - MULLIGHAN, C.G.; ZHANG, J.; HARVEY, R.C.; COLLINS-UNDERWOOD, J.R.; SCHULMAN, B.A.; PHILLIPS, L.A.; TASIAN, S.K.; LOH, M.L.; SU, X., "JAK mutations in high-risk childhood acute lymphoblastic leukemia", PROC. NATL. ACAD. SCI. U. S. A., (2009), vol. 106, pages 9414 - 9418
    - NAKA, T.; NISHIMOTO, N.; KISHIMOTO, T., "The paradigm of IL-6: from basic science to medicine", ARTHRITIS RES., (2002), vol. 4, pages S233 - S242
    - O'DELL, J.R., "Therapeutic Strategies for Rheumatoid Arthritis", N. ENGL. J. MED., (2004), vol. 350, pages 2591 - 2602
    - O'SULLIVAN, L.A.; LIONGUE, C.; LEWIS, R.S.; STEPHENSON, S.E.M.; WARD, A.C., "Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease", MOL. IMMUNOL., (2007), vol. 44, pages 2497 - 2506
    - PUNWANI, N.; SCHERLE, P.; FLORES, R.; SHI, J.; LIANG, J.; YELESWARAM, S.; LEVY, R.; WILLIAMS, W.; GOTTLIEB, A., "Preliminary clinical activity of a topical JAKl/2 inhibitor in the treatment of psoriasis", J. AM. ACAD. DERMATOL., (2012), vol. 67, pages 658 - 664
    - SMOLEN, J.S.; STEINER, G., "Therapeutic strategies for rheumatoid arthritis", NAT. REV. DRUG DISCOV., (2003), vol. 2, pages 473 - 488
    - TAM, L.; MCGLYNN, L.M.; TRAYNOR, P.; MUKHERJEE, R.; BARTLETT, J.M.S.; EDWARDS, J., "Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer", BR. J. CANCER, (2007), vol. 97, pages 378 - 383
    - VAINCHENKER, W.; DUSA, A.; CONSTANTINESCU, S.N., "JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies", SEMIN. CELL DEV. BIOL., (2008), vol. 19, pages 385 - 393
    - "Therapeutic potential of JAK2 inhibitors. ASH Educ", VERSTOVSEK, S., Program Book 2009, (2009), pages 636 - 642
    - XIANG, Z.; ZHAO, Y.; MITAKSOV, V.; FREMONT, D.H.; KASAI, Y.; MOLITORIS, A.; RIES, R.E.; MINER, T.L.; MCLELLAN, M.D.; DIPERSIO, J.F, "Identification of somatic JAKl mutations in patients with acute myeloid leukemia", BLOOD, (2008), vol. 111, pages 4809 - 4812
    - ZENZ, R.; EFERL, R.; KENNER, L.; FLORIN, L.; HUMMERICH, L.; MEHIC, D.; SCHEUCH, H.; ANGEL, P.; TSCHACHLER, E.; WAGNER, E.F., "Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins", NATURE, (2005), vol. 437, pages 369 - 375
    - ZHANG, Q.; NOWAK, I.; VONDERHEID, E.C.; ROOK, A.H.; KADIN, M.E.; NOWELL, P.C.; SHAW, L.M.; WASIK, M.A., "Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome", PROC. NATL. ACAD. SCI. U. S. A., (1996), vol. 93, pages 9148 - 9153
    - ZIKHERMAN, J.; WEISS, A., "Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease", J. CLIN. INVEST., (2011), vol. 121, pages 4618 - 4621
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.